New Enterprise Associates

New Enterprise Associates, Inc. is a private equity and venture capital firm established in 1977 and headquartered in Menlo Park, California, with additional offices in India and China. The firm specializes in investments across various stages of company development, including seed, start-up, early stage, and later stage, with a focus on sectors such as information technology, healthcare, and energy technology. NEA's investment strategy encompasses a wide range of industries, including consumer internet, software, biotechnology, medical devices, and alternative energy. With over $19 billion in cumulative committed capital, the firm has a notable track record, having participated in more than 210 portfolio company IPOs and over 360 acquisitions. NEA aims to invest between $0.05 million and $20 million, targeting both domestic and international markets, particularly in Asia and the Americas.

Michael James Barrett

Partner Emeritus

Kate Barrett

Marketing Partner

Peter J. Barris

Chairman

Ronald D. Bernal

Venture Partner

Ron Bernal

Venture Partner

Tak Cheung

Partner

Philip Chopin

Managing Director

Louis Citron

Chief Administrative Officer and Chief Legal Officer

Robert Croce

Venture Advisor

Bala Deshpande

Sr. Managing Director, India

Lexi Eisenberg

Associate

Anthony A. Florence

Managing General Partner, Technology

Tony Florence

General Partner

Carol Gallagher

Advisor

Tracy Howe

Investment Professional

Suzanne Hooper King

Partner

Liza Landsman

General Partner

Michael Li

Investor

Tiffany Luck

Partner

Joshua Makower

General Partner

Edward T. Mathers

Partner

John Nehra

Retired Special Partner

Michael D. O'Dell

Venture Partner

Santhosh Palani

Principal

Greg Papadopoulos

Venture Partner

Michele Park

Partner

Arno Allan Penzias

Venture Advisor

Eugene A. Trainor

COO

James G. Treybig

Venture Advisor

Paul Walker

General Partner

Harry Weller

Former General Partner

Past deals in Seattle, WA

Tune Therapeutics

Series A in 2021
Tune Therapeutics is focused on developing innovative cell and gene therapies that utilize epigenetic programming to address serious diseases. By harnessing the potential of the epigenome, the company aims to create new therapeutic pathways that modify biological functions without changing the underlying DNA sequence. This approach seeks to provide effective treatments for complex and widespread diseases, positioning Tune Therapeutics at the forefront of advancements in epigenetic medicine.

Shape Therapeutics

Series B in 2021
Shape Therapeutics is a biotechnology company focused on advancing RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic ailments. Founded in 2018 and based in Seattle, Washington, the company utilizes its proprietary RNAfix technology to harness the natural human cellular machinery for RNA editing. This innovative approach aims to minimize the risks of immunogenicity, cellular toxicity, and unintended DNA alterations that are often associated with traditional CRISPR-based methods, positioning Shape Therapeutics as a leader in the development of safe and effective gene therapies.

Shape Therapeutics

Series B in 2021
Shape Therapeutics is a biotechnology company focused on advancing RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic ailments. Founded in 2018 and based in Seattle, Washington, the company utilizes its proprietary RNAfix technology to harness the natural human cellular machinery for RNA editing. This innovative approach aims to minimize the risks of immunogenicity, cellular toxicity, and unintended DNA alterations that are often associated with traditional CRISPR-based methods, positioning Shape Therapeutics as a leader in the development of safe and effective gene therapies.

Pulumi

Series B in 2020
Pulumi is a Seattle-based cloud engineering company that offers a way to build, connect, and run modern cloud applications. Pulumi provides the cloud development model: helping Development and DevOps teams get their code to the cloud quickly and collaboratively. Pulumi provides frameworks and libraries to define, deploy, and manage cloud services -- from serverless to container to virtual machines -- using pure code, for any cloud, with clear collaboration for teams and enterprises delivering on the cloud, multi-cloud, and cloud-native application delivery strategies.

Shape Therapeutics

Series A in 2019
Shape Therapeutics is a biotechnology company focused on advancing RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic ailments. Founded in 2018 and based in Seattle, Washington, the company utilizes its proprietary RNAfix technology to harness the natural human cellular machinery for RNA editing. This innovative approach aims to minimize the risks of immunogenicity, cellular toxicity, and unintended DNA alterations that are often associated with traditional CRISPR-based methods, positioning Shape Therapeutics as a leader in the development of safe and effective gene therapies.

Shape Therapeutics

Series A in 2019
Shape Therapeutics is a biotechnology company focused on advancing RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic ailments. Founded in 2018 and based in Seattle, Washington, the company utilizes its proprietary RNAfix technology to harness the natural human cellular machinery for RNA editing. This innovative approach aims to minimize the risks of immunogenicity, cellular toxicity, and unintended DNA alterations that are often associated with traditional CRISPR-based methods, positioning Shape Therapeutics as a leader in the development of safe and effective gene therapies.

AppSheet

Series A in 2019
AppSheet is the intelligent no-code platform for business apps. It also enables business users to leverage their business data and build powerful, code-free apps. The company connects with a range of data sources including spreadsheets on Google Drive, Office 365, Dropbox, and Box, relational databases like SQLServer, MySQL, Postgres, AWS Aurora, and Oracle, cloud SaaS services like Salesforce, Smartsheet, AirTable, and many more. AppSheet quickly generates a working application that can be customized, enhanced, branded and deployed. The apps can be rich in function (offline access, workflow rules, machine learning, etc) and run on the web, iOS, Android, and messaging platforms. AppSheet was founded in 2014 and is headquartered in Seattle, WA, USA.

Igneous

Series C in 2019
Igneous Systems, Inc., founded in October 2013 and headquartered in Seattle, Washington, specializes in enterprise data center infrastructures and offers a comprehensive Unstructured Data Management (UDM) as-a-Service solution. This innovative service provides data-centric organizations with enhanced visibility, protection, and mobility for their unstructured data at scale. By integrating various UDM functions into a single, cloud-native platform, Igneous enables businesses to maximize the value of their data while minimizing risks and optimizing the use of IT resources.

IOpipe

Seed Round in 2018
IOpipe is a DevOps platform specifically designed for serverless applications, managing billions of events monthly. It offers a comprehensive toolbox for developing, monitoring, and operating these applications, addressing the unique challenges that arise from the shift towards serverless computing. The platform features an open-source module that enables real-time telemetry, tracing, profiling, alerts, logs, and error tracking, allowing developers to gain insights into the performance and operations of their serverless functions, such as those running on Amazon Lambda. By adopting a customer-centric approach, IOpipe collaborates closely with users to resolve challenges effectively. The company emphasizes building a remote-first, diverse team committed to delivering a top-tier product for serverless development and operations.

Igneous

Series B in 2018
Igneous Systems, Inc., founded in October 2013 and headquartered in Seattle, Washington, specializes in enterprise data center infrastructures and offers a comprehensive Unstructured Data Management (UDM) as-a-Service solution. This innovative service provides data-centric organizations with enhanced visibility, protection, and mobility for their unstructured data at scale. By integrating various UDM functions into a single, cloud-native platform, Igneous enables businesses to maximize the value of their data while minimizing risks and optimizing the use of IT resources.

CTI

Post in 2018
CTI BioPharma Corp. a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin's lymphoma; Brostallicin, which is in first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P. The company was founded in 1991 and is headquartered in Seattle, Washington.

IOpipe

Seed Round in 2017
IOpipe is a DevOps platform specifically designed for serverless applications, managing billions of events monthly. It offers a comprehensive toolbox for developing, monitoring, and operating these applications, addressing the unique challenges that arise from the shift towards serverless computing. The platform features an open-source module that enables real-time telemetry, tracing, profiling, alerts, logs, and error tracking, allowing developers to gain insights into the performance and operations of their serverless functions, such as those running on Amazon Lambda. By adopting a customer-centric approach, IOpipe collaborates closely with users to resolve challenges effectively. The company emphasizes building a remote-first, diverse team committed to delivering a top-tier product for serverless development and operations.

SafeRide, Inc

Seed Round in 2017
SafeRide, Inc. is a San Francisco-based company that develops a digital health platform and mobile application designed to facilitate non-emergency medical transport (NEMT) for patients. The platform allows healthcare providers to efficiently book and manage transportation, addressing issues such as appointment no-shows and future scheduling needs. Key features include the ability to send appointment reminders, real-time text alerts, and ride tracking, ensuring patient safety and quality service. SafeRide also offers tools to identify and monitor at-risk patients before they require critical care. Since its founding in 2015, the company has expanded its service network to include major cities such as Los Angeles, Seattle, Portland, St. Louis, and the greater New York area.

Mighty AI

Series B in 2017
Mighty AI delivers training data to companies that build computer vision models for autonomous vehicles. Its platform combines guaranteed accuracy with scale and expertise, thanks to its full stack of annotation software, consulting and managed services, proprietary machine learning, and global community of pre-qualified annotators. Founded in 2014, Mighty AI is headquartered in Seattle, Washington.
Cascadian Therapeutics, a clinical-stage biopharmaceutical company, researches and develops, and sells therapeutic products for the treatment of cancer in the United States. The company lead clinical-stage product candidate is tucatinib, an orally active and HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin. It is also developing Checkpoint kinase 1, a protein kinase that is in pre-clinical studies to regulate the cell division cycle, as well as to DNA damage and replication stress. In addition, the company focuses on the development of novel antibodies and T-cell immunoreceptor with Ig and ITM domains, an inhibitory receptor expressed on T-cells and NK cells that negatively regulate immune response to cancers. It has a license agreement with Array BioPharma Inc. to develop, manufacture and commercialize tucatinib; research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; and collaboration agreement with Adimab LLC for the discovery of novel antibodies against d immunotherapy targets in oncology.

AppSheet

Seed Round in 2015
AppSheet is the intelligent no-code platform for business apps. It also enables business users to leverage their business data and build powerful, code-free apps. The company connects with a range of data sources including spreadsheets on Google Drive, Office 365, Dropbox, and Box, relational databases like SQLServer, MySQL, Postgres, AWS Aurora, and Oracle, cloud SaaS services like Salesforce, Smartsheet, AirTable, and many more. AppSheet quickly generates a working application that can be customized, enhanced, branded and deployed. The apps can be rich in function (offline access, workflow rules, machine learning, etc) and run on the web, iOS, Android, and messaging platforms. AppSheet was founded in 2014 and is headquartered in Seattle, WA, USA.

Mighty AI

Series A in 2015
Mighty AI delivers training data to companies that build computer vision models for autonomous vehicles. Its platform combines guaranteed accuracy with scale and expertise, thanks to its full stack of annotation software, consulting and managed services, proprietary machine learning, and global community of pre-qualified annotators. Founded in 2014, Mighty AI is headquartered in Seattle, Washington.

Turi

Series B in 2015
Turi is a machine learning platform that creates big data analytics products for its users. This open source project was initially intended for applying large scale machine learning to graph analysis. The functionality of its product has since been greatly expanded to include tables, text, as well as images and is now in broad use to make recommendations, detect fraud, conduct customer sentiment analysis, and generally build predictive apps at many notable e-tailers, service providers, and Fortune 5000 firms, including Zillow, ExxonMobil, StumbleUpon, Adobe, Pandora, and Bosch. Turi was launched as Dato in 2013 by Danny Bickson, Haijie Gu, Yucheng Low, Joseph Gonzalez, and Carlos Guestrin. It is based in Seattle, W.A.

Mighty AI

Seed Round in 2014
Mighty AI delivers training data to companies that build computer vision models for autonomous vehicles. Its platform combines guaranteed accuracy with scale and expertise, thanks to its full stack of annotation software, consulting and managed services, proprietary machine learning, and global community of pre-qualified annotators. Founded in 2014, Mighty AI is headquartered in Seattle, Washington.

Igneous

Series A in 2014
Igneous Systems, Inc., founded in October 2013 and headquartered in Seattle, Washington, specializes in enterprise data center infrastructures and offers a comprehensive Unstructured Data Management (UDM) as-a-Service solution. This innovative service provides data-centric organizations with enhanced visibility, protection, and mobility for their unstructured data at scale. By integrating various UDM functions into a single, cloud-native platform, Igneous enables businesses to maximize the value of their data while minimizing risks and optimizing the use of IT resources.

Turi

Series A in 2013
Turi is a machine learning platform that creates big data analytics products for its users. This open source project was initially intended for applying large scale machine learning to graph analysis. The functionality of its product has since been greatly expanded to include tables, text, as well as images and is now in broad use to make recommendations, detect fraud, conduct customer sentiment analysis, and generally build predictive apps at many notable e-tailers, service providers, and Fortune 5000 firms, including Zillow, ExxonMobil, StumbleUpon, Adobe, Pandora, and Bosch. Turi was launched as Dato in 2013 by Danny Bickson, Haijie Gu, Yucheng Low, Joseph Gonzalez, and Carlos Guestrin. It is based in Seattle, W.A.

Pure Energies Group

Private Equity Round in 2013
PURE Energies is committed to being the most trusted energy advisor to homeowners by facilitating the adoption of solar energy and home conservation products across North America for the benefit of communities and future generations. We are a Canadian company built on Ontario’s Green Energy Act and we have expanded internationally across the US with the acquisitions of San Francisco-based One Block off the Grid and Seattle-based Cooler Planet. With locations in Toronto, Mississauga and San Francisco, we are now proudly representing Canada in the rapidly expanding international solar market.

Immunex

Venture Round in 1992
Immunex Corporation, founded in 1981 and based in Seattle, Washington, specializes in the development, manufacturing, and marketing of therapeutic products aimed at treating cancer, infectious diseases, and autoimmune disorders. The company's notable products include Enbrel, utilized for rheumatoid arthritis; Novantrone, which addresses acute nonlymphocytic leukemia and pain from prostate cancer; and Leukine, intended for bone marrow transplant patients. Immunex has engaged in strategic alliances, notably with American Home Products, to enhance its market reach. In 2002, Immunex Corporation was acquired by Amgen, Inc., marking a significant shift in its corporate structure while continuing its focus on therapeutic innovations.